Articles

Presenting infigratinib’s preclinical data

Preclinical data demonstrates the potential of QED Therapeutics’ infigratinib in multiple FGFR+ tumor types
Brought to you byDDNews Staff
| 2 min read

SAN FRANCISCO—QED Therapeutics, a biotechnology company focused on precision medicine for FGFR-driven diseases, announced yesterday the presentation of preclinical data demonstrating the potential of their lead investigational candidate infigratinib for treating FGFR-driven cancers derived from multiple tissue types. The data, in a poster entitled “Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors,” was presented during the currently ongoing AACR 2019 Annual Meeting.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.